Sionna Therapeutics (NASDAQ:SION) Director Orbimed Advisors Llc Sells 29,063 Shares

Sionna Therapeutics, Inc. (NASDAQ:SION) Director Orbimed Advisors Llc sold 29,063 shares of the business’s stock in a transaction dated Tuesday, February 3rd. The shares were sold at an average price of $44.58, for a total transaction of $1,295,628.54. Following the completion of the sale, the director directly owned 3,530,702 shares of the company’s stock, valued at approximately $157,398,695.16. The trade was a 0.82% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link.

Orbimed Advisors Llc also recently made the following trade(s):

• On Monday, February 2nd, Orbimed Advisors Llc sold 1,890 shares of Sionna Therapeutics stock. The stock was sold at an average price of $44.57, for a total transaction of $84,237.30.
• On Wednesday, December 24th, Orbimed Advisors Llc sold 33,356 shares of Sionna Therapeutics stock. The shares were sold at an average price of $44.55, for a total transaction of $1,486,009.80.
• On Friday, December 19th, Orbimed Advisors Llc sold 875 shares of Sionna Therapeutics stock. The stock was sold at an average price of $44.49, for a total transaction of $38,928.75.
• On Thursday, December 18th, Orbimed Advisors Llc sold 100 shares of Sionna Therapeutics stock. The shares were sold at an average price of $44.49, for a total transaction of $4,449.00.
• On Wednesday, December 17th, Orbimed Advisors Llc sold 900 shares of Sionna Therapeutics stock. The shares were sold at an average price of $44.50, for a total value of $40,050.00.
• On Wednesday, November 26th, Orbimed Advisors Llc sold 1,600 shares of Sionna Therapeutics stock. The stock was sold at an average price of $44.49, for a total value of $71,184.00.
• On Tuesday, November 25th, Orbimed Advisors Llc sold 11,890 shares of Sionna Therapeutics stock. The shares were sold at an average price of $44.60, for a total transaction of $530,294.00.
• On Monday, November 24th, Orbimed Advisors Llc sold 94,583 shares of Sionna Therapeutics stock. The shares were sold at an average price of $44.54, for a total transaction of $4,212,726.82.

Sionna Therapeutics Stock Performance

Shares of Sionna Therapeutics stock traded down $3.17 during trading on Wednesday, reaching $41.31. 313,154 shares of the company’s stock were exchanged, compared to its average volume of 306,528. Sionna Therapeutics, Inc. has a 1-year low of $7.26 and a 1-year high of $45.00. The firm’s 50-day moving average price is $41.45 and its 200 day moving average price is $32.74. The company has a market cap of $1.84 billion and a P/E ratio of -8.48.

Sionna Therapeutics (NASDAQ:SION) last announced its quarterly earnings results on Wednesday, November 5th. The company reported ($0.46) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.52) by $0.06.

Hedge Funds Weigh In On Sionna Therapeutics

Large investors have recently added to or reduced their stakes in the business. Bank of America Corp DE increased its holdings in Sionna Therapeutics by 8.8% during the 3rd quarter. Bank of America Corp DE now owns 6,541 shares of the company’s stock worth $192,000 after purchasing an additional 529 shares in the last quarter. BNP Paribas Financial Markets lifted its holdings in shares of Sionna Therapeutics by 35.2% in the third quarter. BNP Paribas Financial Markets now owns 2,380 shares of the company’s stock valued at $70,000 after purchasing an additional 619 shares in the last quarter. GF Fund Management CO. LTD. purchased a new position in shares of Sionna Therapeutics during the fourth quarter valued at approximately $36,000. Russell Investments Group Ltd. bought a new stake in Sionna Therapeutics during the third quarter worth $30,000. Finally, Mirae Asset Global Investments Co. Ltd. purchased a new stake in Sionna Therapeutics in the 4th quarter valued at $89,000.

Analysts Set New Price Targets

Several equities analysts have issued reports on the stock. Weiss Ratings restated a “sell (e+)” rating on shares of Sionna Therapeutics in a research report on Monday, December 29th. BTIG Research restated a “buy” rating and set a $58.00 price target on shares of Sionna Therapeutics in a report on Wednesday, January 14th. Wall Street Zen raised shares of Sionna Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, December 13th. Royal Bank Of Canada reissued an “underperform” rating and issued a $24.00 price objective on shares of Sionna Therapeutics in a research note on Monday, December 1st. Finally, Lifesci Capital initiated coverage on shares of Sionna Therapeutics in a research report on Tuesday, December 23rd. They set an “outperform” rating and a $60.00 price objective for the company. One equities research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and two have issued a Sell rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $45.43.

Sionna Therapeutics Company Profile

Sionna Therapeutics is a clinical-stage biotechnology company dedicated to developing next-generation RNA therapeutics for oncology and immunology indications. Leveraging proprietary lipid nanoparticle and coacervate delivery technologies, the company aims to overcome key challenges associated with stability, targeting and immune activation that have historically limited the clinical performance of mRNA-based medicines. Its strategic focus spans both solid tumors and hematological malignancies, as well as selected autoimmune disorders, reflecting a broad ambition to harness the power of messenger RNA in diverse therapeutic areas.

At the heart of Sionna’s approach is a platform that combines optimized ionizable lipids with bespoke surface chemistries to enhance payload delivery, intracellular release and endosomal escape.